Skip to main content
. 2019 Sep 1;39(3):502–512. doi: 10.7705/biomedica.4235

Table 2. Cost-effectiveness of OPT compared to OPT plus ICD.

Strategy Costs (USD) Incremental cost QALY Incremental QALY ICER
Base-case
OPT 974 2.6056
OPT + ICD 10,992 10,018 3.3653 0.7596 13,187
Sensitivity analysis - time horizon (5 and 20 years)
OPT 890 2.3859
OPT + ICD 10,322 9,432 2.8445 0.4585 20,569
OPT 987 2.6385
OPT + ICD 11,194 10,207 3.5225 0.8840 11,546
Analysis by subgroups (ischemic and non-ischemic)
OPT 973 2.6029
OPT + ICD 11,314 10,341 3.5449 0.9420 10,977
OPT 1,243 3.3146
OPT + ICD 12,252 11,008 4.0488 0.7342 14,992

OPT: Optimal pharmaceutical therapy; ICD: Implantable cardioverter defibrillator; ICER: Incremental costeffectiveness ratio; QALY: Quality-adjusted life years